Favipiravir

Antiviral, Systemic · Pyrazine

Indications

Influenza unresponsive to conventional treatment. Mild-to-moderate COVID-19.

Dosage

Adults: Influenza unresponsive to conventional treatment: Day 1: 1600 mg twice daily. Day 2-5: 600 mg twice daily. COVID-19: Day 1: 1800 mg twice daily. Day 2 onwards: 800 mg twice daily, up to a maximum of 14 days. Children: Not recommended.

Adverse Effects

Nausea, vomiting, diarrhoea, chest pain, decreased appetite, increased AST and ALT, increased blood uric acid, decreased neutrophil count, decreased WBCs count.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Contraindications: Severe hepatic and renal impairment. Precautions: Elderly. Hyperuricaemia/gout.

Interactions

Pyrazinamide, repaglinide, theophylline, famciclovir, sulindac.

Advice to Patient

Be careful while driving, operating machinery and doing tasks that require alertness.

Pharmacokinetics

Metabolism: Hepatic via aldehyde oxidase and partly via xanthine oxidase. Half-life elimination: 2-5.5 hrs. Excretion: Urine.

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.